Bask­ing rais­es $55M; Ser­o­ba’s fourth fund; Ve­ra up­sizes its pub­lic of­fer­ing

Plus, news about Abeona Ther­a­peu­tics and Gravi­ton:

Bask­ing Bio­sciences rais­es $55M: The Colum­bus, OH-based start­up reeled in fund­ing from half a dozen in­vestors, in­clud­ing ARCH Ven­ture Part­ners, whose man­ag­ing di­rec­tor Steven Gillis will join Bask­ing’s board as chair. The biotech plans to start a Phase II for its RNA ap­tamer BB-031 in pa­tients with acute is­chemic stroke this year. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER